Financials

  • Market Capitalization 892.87 M
  • Employee 19
  • Founded 2007
  • CEO William H. Collier
  • Website www.arbutusbio.com
  • Headquarter British Columbia, Canada
  • FIGI BBG000RR8V85
  • Industry Biotechnology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
5.42
Price to sales ratio
4.58

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
2533
DBVT
DBV Technologies S.A. - American Depositary Shares
15.62 USD-1.88%-4.76%-14.69%+61.36%924.84 M USD
2541
LBRX
LB Pharmaceuticals Inc - Common Stock
31.76 USD-0.81%-6.75%+10.51%+67.16%910.77 M USD
2555
GERN
Geron Corporation - Common Stock
1.41 USD+2.17%-4.73%+22.61%+10.16%904.54 M USD
2567
TBPH
Theravance Biopharma, Inc. - Ordinary Shares
16.94 USD+0.12%-0.35%+3.17%+18.05%873.31 M USD

Frequently asked questions about Arbutus Biopharma Corporation - Common Stock

What is the Arbutus Biopharma Corporation - Common Stock stock price today?

The current price of Arbutus Biopharma Corporation - Common Stock (ABUS) is 4.52. Over the past 24 hours, the stock has changed by -1.95%. Follow the ABUS chart for real-time price dynamics.

What is the stock ticker of Arbutus Biopharma Corporation - Common Stock?

Arbutus Biopharma Corporation - Common Stock trades under the ticker ABUS. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is Arbutus Biopharma Corporation - Common Stock stock going up?

ABUS has changed by -10.50% over the last week, +3.91% over the last month, and +44.41% over the last year. Review the chart to see whether the current move is part of a broader trend.

What was Arbutus Biopharma Corporation - Common Stock net income for the last quarter?

Arbutus Biopharma Corporation - Common Stock reported net income of 169.69 M for the last quarter. The previous quarter showed -3.76 M, which means net income changed by +4617.97%.

How many employees does Arbutus Biopharma Corporation - Common Stock have?

As of the latest available data, Arbutus Biopharma Corporation - Common Stock has 19 employees. Workforce size can provide additional context about the company's scale and operations.

What is Arbutus Biopharma Corporation - Common Stock EBITDA?

Arbutus Biopharma Corporation - Common Stock EBITDA is 168.92 M, and its EBITDA margin is 94.3%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.

How can I buy Arbutus Biopharma Corporation - Common Stock stock?

You can buy Arbutus Biopharma Corporation - Common Stock (ABUS) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in Arbutus Biopharma Corporation - Common Stock stock?

Investing in Arbutus Biopharma Corporation - Common Stock requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the ABUS chart and related analysis on metatrader.com as part of your research.

Arbutus Biopharma Corporation - Common Stock

Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection. It is headquartered in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007.

News